SCHEMBL20097197

SCHEMBL20097197

Cc1ccc2c3c(C)cccc3n(CCNCC3OC(n4cnc5c(N)ncnc54)C(O)C3O)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NNMT P40261 1/20 0.53
▸ DOT1L Q8TEK3 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ CARM1 Q86X55 1/20 0.48
▸ DPP4 P27487 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ SLC28A1 O00337 1/20 0.48
▸ MAP3K7 O43318 1/20 0.48
▸ SLC28A2 O43868 1/20 0.48
▸ GAPDH P04406 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ADORA2A P29274 1/20 0.48
▸ ADORA2B P29275 1/20 0.48
▸ ADORA1 P30542 1/20 0.48
▸ STAT6 P42226 1/20 0.48
▸ PI4KA P42356 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ PI4K2B Q8TCG2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20096733 0.93 DOT1L (0.54) NNMTDOT1LATMDPP4MEN1
SCHEMBL20096729 0.92 NNMT (0.52) NNMTDOT1LATMCARM1DPP4
SCHEMBL20097057 0.91 DOT1L (0.54) NNMTDOT1LATMDPP4MEN1
SCHEMBL20097198 0.91 DOT1L (0.54) NNMTDOT1LATMCARM1ADORA1
SCHEMBL20096725 0.89 DOT1L (0.52) NNMTDOT1LATMDPP4MEN1
SCHEMBL20096730 0.87 DOT1L (0.54) NNMTDOT1LATMDPP4MEN1
SCHEMBL20096948 0.86 DOT1L (0.50) NNMTDOT1LDPP4MEN1SLC28A1
SCHEMBL20096726 0.86 DOT1L (0.50) NNMTDOT1LDPP4MEN1SLC28A1
SCHEMBL20097029 0.85 DOT1L (0.49) NNMTDOT1LATMDPP4MEN1
SCHEMBL20097058 0.84 DOT1L (0.54) NNMTDOT1LATMDPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 — — US disclosed
WO-2018075947-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS POLRMT, EIF2AK2, NSUN3 NNMT 865/4885DOT1L 2274/4885ATM 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback